Mutant Calreticulin Requires Both Its Mutant C-terminus and the Thrombopoietin Receptor for Oncogenic Transformation

Autor: Elf, S, Abdelfattah, NS, Chen, E, Perales-Patón, J, Rosen, EA, Ko, A, Peisker, F, Florescu, N, Giannini, S, Wolach, O, Morgan, EA, Tothova, Z, Losman, JA, Schneider, RK, Al-Shahrour, F, Mullally, A

Somatic mutations in calreticulin (CALR) are present in approximately 40% of patients with myeloproliferative neoplasms (MPN), but the mechanism by which mutant CALR is oncogenic remains unclear. Here, we demonstrate that expression of mutant CALR al

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=core_ac_uk__::72e86008ec72edcaa99d6664d6ecc02a
https://eprints.whiterose.ac.uk/99394/1/CD-15-1434R1_Manuscript.pdf

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

COVID-19 Outcomes Among Hematopoietic Cell Transplant and Chimeric Antigen Receptor T-Cell Recipients in the Era of SARS-CoV-2 Omicron Variants and COVID-19 Therapeutics.

Autor: Rosen EA; Division of Allergy and Infectious Diseases, University of Washington, Seattle, Washington; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, Washington. Electronic address: erosen@fredhutch.org., Krantz EM; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, Washington., McCulloch DJ; Division of Allergy and Infectious Diseases, University of Washington, Seattle, Washington; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, Washington; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, Washington., Wilson MH; Department of Quality, Fred Hutchinson Cancer Center, Seattle, Washington., Tverdek F; Department of Pharmacy, Fred Hutchinson Cancer Center, Seattle, Washington; Department of Pharmacy, University of Washington, Seattle, Washington., Kassamali Escobar Z; Department of Pharmacy, Fred Hutchinson Cancer Center, Seattle, Washington; Department of Pharmacy, University of Washington, Seattle, Washington., Drucker D; Department of Pharmacy, University of Washington, Seattle, Washington., Sanchez E; Division of Allergy and Infectious Diseases, University of Washington, Seattle, Washington; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, Washington., Ueda Oshima M; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, Washington; Division of Hematology and Oncology, University of Washington, Seattle, Washington., Mielcarek M; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, Washington; Division of Hematology and Oncology, University of Washington, Seattle, Washington., Gauthier J; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, Washington; Division of Hematology and Oncology, University of Washington, Seattle, Washington., Pergam SA; Division of Allergy and Infectious Diseases, University of Washington, Seattle, Washington; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, Washington; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, Washington., Hill JA; Division of Allergy and Infectious Diseases, University of Washington, Seattle, Washington; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, Washington; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, Washington., Liu C; Division of Allergy and Infectious Diseases, University of Washington, Seattle, Washington; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, Washington; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, Washington.

Publikováno v: Transplantation and cellular therapy [Transplant Cell Ther] 2024 Nov; Vol. 30 (11), pp. 1108.e1-1108.e11. Date of Electronic Publication: 2024 Aug 22.